JP2024527380A5 - - Google Patents
Info
- Publication number
- JP2024527380A5 JP2024527380A5 JP2024501166A JP2024501166A JP2024527380A5 JP 2024527380 A5 JP2024527380 A5 JP 2024527380A5 JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024527380 A5 JP2024527380 A5 JP 2024527380A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- rnai
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220400P | 2021-07-09 | 2021-07-09 | |
| US63/220,400 | 2021-07-09 | ||
| PCT/IB2022/056278 WO2023281434A1 (en) | 2021-07-09 | 2022-07-07 | Use of oligonucleotides for individuals with renal impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527380A JP2024527380A (ja) | 2024-07-24 |
| JP2024527380A5 true JP2024527380A5 (cg-RX-API-DMAC7.html) | 2025-07-08 |
Family
ID=82703082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501166A Pending JP2024527380A (ja) | 2021-07-09 | 2022-07-07 | 腎機能障害を有する個体へのオリゴヌクレオチドの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240336921A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4367241A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527380A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117616121A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3224600A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202323525A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023281434A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| EA008940B1 (ru) | 2002-09-13 | 2007-10-26 | Репликор, Инк. | Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| JP5775581B2 (ja) | 2010-08-20 | 2015-09-09 | レプリコール インコーポレーティッド | オリゴヌクレオチドキレート錯体 |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| KR20170029577A (ko) | 2014-07-10 | 2017-03-15 | 레플리코르 인코포레이티드 | B형 간염 및 d형 간염 바이러스 감염의 치료 방법 |
| JOP20190015A1 (ar) * | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US20200147124A1 (en) | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| TWI872048B (zh) * | 2019-02-07 | 2025-02-11 | 美商艾羅海德製藥公司 | 用於B型肝炎病毒感染之RNAi劑 |
| TW202103698A (zh) * | 2019-04-18 | 2021-02-01 | 美商健生醫藥公司 | 用於治療b型肝炎病毒感染之組合療法 |
| US20200332297A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
-
2022
- 2022-07-07 CN CN202280048358.4A patent/CN117616121A/zh active Pending
- 2022-07-07 CA CA3224600A patent/CA3224600A1/en active Pending
- 2022-07-07 JP JP2024501166A patent/JP2024527380A/ja active Pending
- 2022-07-07 EP EP22747759.3A patent/EP4367241A1/en active Pending
- 2022-07-07 WO PCT/IB2022/056278 patent/WO2023281434A1/en not_active Ceased
- 2022-07-07 US US18/577,450 patent/US20240336921A1/en active Pending
- 2022-07-08 TW TW111125691A patent/TW202323525A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI761311B (zh) | 拮抗b型肝炎病毒之組成物和藥劑及彼等之用途 | |
| TWI872048B (zh) | 用於B型肝炎病毒感染之RNAi劑 | |
| TWI702045B (zh) | 治療甲狀腺素運載蛋白(ttr)調節之澱粉樣變性的方法 | |
| FI3837366T3 (fi) | Hepatiitti b -viruksen (hbv) dsrna-ainekoostumuksia ja niiden käyttömenetelmiä | |
| JP2024153797A5 (cg-RX-API-DMAC7.html) | ||
| JP6922030B2 (ja) | B型肝炎およびd型肝炎ウイルス感染の治療のための方法 | |
| US20240052350A1 (en) | Oligonucleotide and use thereof against hepatitis b virus and hepatitis d virus | |
| JP2022532211A5 (cg-RX-API-DMAC7.html) | ||
| JP2022515778A5 (cg-RX-API-DMAC7.html) | ||
| US11685921B2 (en) | Molecules and agents for treating hepatitis B virus | |
| JP2025096283A5 (cg-RX-API-DMAC7.html) | ||
| JP2024544532A5 (cg-RX-API-DMAC7.html) | ||
| US20240425859A1 (en) | Pharmaceutical combinations for treatment of hbv | |
| WO2010008474A4 (en) | Methods for treating multiple sclerosis using antisense oligonucleotides | |
| CN114057816B (zh) | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 | |
| JP7376679B2 (ja) | Hbv感染の処置のためのeyp001とifnの相乗効果 | |
| JP2024528659A5 (cg-RX-API-DMAC7.html) | ||
| CN121003688A (zh) | 一种dsRNA与干扰素的联合治疗 | |
| HK40065449A (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| HK40092095A (en) | Pharmaceutical combined formulation for prevention or treatment of chronic hepatitis b, use thereof and combined formulation kit containing the same | |
| HK40092095B (en) | Pharmaceutical combined formulation for prevention or treatment of chronic hepatitis b, use thereof and combined formulation kit containing the same | |
| TH2101000823A (th) | องค์ประกอบสาร dsRNA ไวรัสตับอักเสบ B (HBV) และวิธีการใช้ขององค์ประกอบนั้น |